{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:11:29Z","timestamp":1783354289230,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005331","name":"American Brain Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00415-020-09944-8","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T13:30:42Z","timestamp":1591191042000},"page":"2790-2796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["COVID-19 in teriflunomide-treated patients with multiple sclerosis"],"prefix":"10.1007","volume":"267","author":[{"given":"Amir Hadi","family":"Maghzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Houtchens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Preziosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Ionete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana D.","family":"Beretich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Stankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahamat","family":"Tauhid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Cabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idanis","family":"Berriosmorales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara H. W.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Sloane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard L.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8601-5534","authenticated-orcid":false,"given":"Rohit","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"9944_CR1","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W Guan","year":"2020","unstructured":"Guan W, Ni Z, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708\u20131720. https:\/\/doi.org\/10.1056\/NEJMoa2002032","journal-title":"N Engl J Med"},{"key":"9944_CR2","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054\u20131062. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3","journal-title":"Lancet"},{"key":"9944_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13054-020-2818-6","volume":"24","author":"AC Cunningham","year":"2020","unstructured":"Cunningham AC, Goh HP, Koh D (2020) Treatment of COVID-19: old tricks for new challenges. Crit Care 24:91. https:\/\/doi.org\/10.1186\/s13054-020-2818-6","journal-title":"Crit Care"},{"key":"9944_CR4","doi-asserted-by":"publisher","first-page":"m1252","DOI":"10.1136\/bmj.m1252","volume":"368","author":"E Mahase","year":"2020","unstructured":"Mahase E (2020) Covid-19: what treatments are being investigated? BMJ 368:m1252. https:\/\/doi.org\/10.1136\/bmj.m1252","journal-title":"BMJ"},{"key":"9944_CR5","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D et al (2020) A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:1787\u20131799. https:\/\/doi.org\/10.1056\/NEJMoa2001282","journal-title":"N Engl J Med"},{"key":"9944_CR6","unstructured":"NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. https:\/\/www.nih.gov\/news-events\/news-releases\/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19. Accessed 15 May 2020"},{"key":"9944_CR7","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD et al (2019) The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 92:e1029\u2013e1040. https:\/\/doi.org\/10.1212\/WNL.0000000000007035","journal-title":"Neurology"},{"key":"9944_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J et al (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77:184\u2013191. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3365","journal-title":"JAMA Neurol"},{"key":"9944_CR9","doi-asserted-by":"publisher","first-page":"e0155795","DOI":"10.1371\/journal.pone.0155795","volume":"11","author":"A Karamyan","year":"2016","unstructured":"Karamyan A, D\u00fcnser MW, Wiebe DJ et al (2016) Critical illness in patients with multiple sclerosis: a matched case-control study. PLoS ONE 11:e0155795. https:\/\/doi.org\/10.1371\/journal.pone.0155795","journal-title":"PLoS ONE"},{"key":"9944_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/ene.12130","volume":"20","author":"S Montgomery","year":"2013","unstructured":"Montgomery S, Hillert J, Bahmanyar S (2013) Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol 20:1153\u20131160. https:\/\/doi.org\/10.1111\/ene.12130","journal-title":"Eur J Neurol"},{"key":"9944_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2015.00520","volume":"6","author":"AJ Steelman","year":"2015","unstructured":"Steelman AJ (2015) Infection as an environmental trigger of multiple sclerosis disease exacerbation. Front Immunol 6:520. https:\/\/doi.org\/10.3389\/fimmu.2015.00520","journal-title":"Front Immunol"},{"key":"9944_CR12","doi-asserted-by":"publisher","first-page":"102073","DOI":"10.1016\/j.msard.2020.102073","volume":"39","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Hawkes C, Lechner-Scott J et al (2020) The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord 39:102073. https:\/\/doi.org\/10.1016\/j.msard.2020.102073","journal-title":"Mult Scler Relat Disord"},{"key":"9944_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","volume":"8","author":"B Barry","year":"2019","unstructured":"Barry B, Erwin AA, Stevens J, Tornatore C (2019) Fingolimod rebound: a review of the clinical experience and management considerations. Neurol Ther 8:241\u2013250. https:\/\/doi.org\/10.1007\/s40120-019-00160-9","journal-title":"Neurol Ther"},{"key":"9944_CR14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/ene.12132","volume":"20","author":"W Kim","year":"2013","unstructured":"Kim W, Kim S-H, Huh S-Y et al (2013) Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. Eur J Neurol 20:975\u2013980. https:\/\/doi.org\/10.1111\/ene.12132","journal-title":"Eur J Neurol"},{"key":"9944_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30147-2","author":"MP Sormani","year":"2020","unstructured":"Sormani MP (2020) An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(20)30147-2[Epub ahead of print, April 30, 2020]","journal-title":"Lancet Neurol"},{"key":"9944_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102120","author":"G Novi","year":"2020","unstructured":"Novi G, Mikulska M, Briano F et al (2020) COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/j.msard.2020.102120[Epub ahead of print, April 15, 2020]","journal-title":"Mult Scler Relat Disord"},{"key":"9944_CR17","doi-asserted-by":"publisher","first-page":"e753","DOI":"10.1212\/NXI.0000000000000753","volume":"7","author":"M Barzegar","year":"2020","unstructured":"Barzegar M, Mirmosayyeb O, Nehzat N et al (2020) COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol Neuroimmunol Neuroinflamm 7:e753. https:\/\/doi.org\/10.1212\/NXI.0000000000000753","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"9944_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/jon.12182","volume":"171","author":"C Lebrun","year":"2015","unstructured":"Lebrun C (2015) The radiologically isolated syndrome. Rev Neurol (Paris) 171:698\u2013706. https:\/\/doi.org\/10.1111\/jon.12182","journal-title":"Rev Neurol (Paris)"},{"key":"9944_CR19","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","volume":"27","author":"Y Shi","year":"2020","unstructured":"Shi Y, Wang Y, Shao C et al (2020) COVID-19 infection: the perspectives on immune responses. Cell Death Differ 27:1451\u20131454. https:\/\/doi.org\/10.1038\/s41418-020-0530-3","journal-title":"Cell Death Differ"},{"key":"9944_CR20","doi-asserted-by":"publisher","first-page":"e1000756","DOI":"10.1371\/journal.ppat.1000756","volume":"6","author":"SL Smits","year":"2010","unstructured":"Smits SL, de Lang A, van den Brand JMA et al (2010) Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog 6:e1000756. https:\/\/doi.org\/10.1371\/journal.ppat.1000756","journal-title":"PLoS Pathog"},{"key":"9944_CR21","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/eji.201546178","volume":"46","author":"M Pinti","year":"2016","unstructured":"Pinti M, Appay V, Campisi J et al (2016) Aging of the immune system: focus on inflammation and vaccination. Eur J Immunol 46:2286\u20132301","journal-title":"Eur J Immunol"},{"key":"9944_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","volume":"74","author":"A Bar-Or","year":"2014","unstructured":"Bar-Or A, Pachner A, Menguy-Vacheron F et al (2014) Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74:659\u2013674. https:\/\/doi.org\/10.1007\/s40265-014-0212-x","journal-title":"Drugs"},{"key":"9944_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1212\/WNL.0b013e31829e6fbf","volume":"81","author":"A Bar-Or","year":"2013","unstructured":"Bar-Or A, Freedman MS, Kremenchutzky M et al (2013) Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology 81:552\u2013558. https:\/\/doi.org\/10.1212\/WNL.0b013e31829e6fbf","journal-title":"Neurology"},{"key":"9944_CR24","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/NXI.0000000000000070","volume":"2","author":"A Bar-Or","year":"2015","unstructured":"Bar-Or A, Wiendl H, Miller B et al (2015) Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neuroimmunol NeuroInflamm 2:e70. https:\/\/doi.org\/10.1212\/NXI.0000000000000070","journal-title":"Neurol Neuroimmunol NeuroInflamm"},{"key":"9944_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2019.109305","volume":"118","author":"G Mei-jiao","year":"2019","unstructured":"Mei-jiao G, Shi-fang L, Yan-yan C et al (2019) Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. Biomed Pharmacother 118:1\u20137. https:\/\/doi.org\/10.1016\/j.biopha.2019.109305","journal-title":"Biomed Pharmacother"},{"key":"9944_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13365-017-0570-8","volume":"23","author":"F Gilli","year":"2017","unstructured":"Gilli F, Li L, Royce DB et al (2017) Treatment of Theiler\u2019s virus-induced demyelinating disease with teriflunomide. J Neurovirol 23:825\u2013838. https:\/\/doi.org\/10.1007\/s13365-017-0570-8","journal-title":"J Neurovirol"},{"key":"9944_CR27","doi-asserted-by":"publisher","first-page":"44266","DOI":"10.18632\/oncotarget.17863","volume":"8","author":"A Bilger","year":"2017","unstructured":"Bilger A, Plowshay J, Ma S et al (2017) Leflunomide\/teriflunomide inhibit Epstein-barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication. Oncotarget 8:44266\u201344280. https:\/\/doi.org\/10.18632\/oncotarget.17863","journal-title":"Oncotarget"},{"key":"9944_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13073-018-0570-1","volume":"10","author":"S Martin","year":"2018","unstructured":"Martin S, Chiramel AI, Schmidt ML et al (2018) A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle. Genome Med 10:58. https:\/\/doi.org\/10.1186\/s13073-018-0570-1","journal-title":"Genome Med"},{"key":"9944_CR29","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.11.983056","author":"R Xiong","year":"2020","unstructured":"Xiong R, Zhang L, Li S et al (2020) Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2. BioRxiv. https:\/\/doi.org\/10.1101\/2020.03.11.983056","journal-title":"BioRxiv"},{"key":"9944_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.clineuro.2013.09.030","volume":"115","author":"C Warnke","year":"2013","unstructured":"Warnke C, St\u00fcve O, Kieseier BC (2013) Teriflunomide for the treatment of multiple sclerosis. Clin Neurol Neurosurg 115:90\u201394. https:\/\/doi.org\/10.1016\/j.clineuro.2013.09.030","journal-title":"Clin Neurol Neurosurg"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09944-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-09944-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09944-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T21:40:34Z","timestamp":1622670034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-09944-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["9944"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-09944-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-28699\/v1","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"1 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MK Houtchens has received consulting fees from Biogen, EMD Serono, Sanofi-Genzyme, Mallinckrodt, Roche and research support from Biogen, EMD Serono, and Sanofi-Genzyme. P Preziosa has received speaking fees from Biogen, ExceMED, Merck Serono, and Novartis. C Ionete has received consulting fees from Sanofi-Genzyme, and research support from Biogen, EMD Serono, and Genentech. JM Stankiewicz has received consulting fees from Biogen, BMS\/Celgene, EMD Serono, Genentech, Sanofi-Genzyme, and Novartis. A Cabot has received speaking fees from Alexion, Biogen, EMD\/Serono, Genentech, Novartis, and Sanofi-Genzyme. JA Sloane has received consulting fees from Biogen, BMS\/Celgene, EMD Serono, Genentech, Alexion, and Sanofi-Genzyme, and research support from National MS Society, Genentech, Biogen, EMD Serono, and Sanofi-Genzyme. MS Freedman has received research or educational grants from EMD Serono, Hoffman-La Roche, and Sanofi-Genzyme, and honoraria, consultation, or speaking fees from Actelion, Alexion, Atara, Bayer, Biogen, BMS\/Celgene, Clene Nanomedicine, EMD Serono, GRI Bio, Hoffman La-Roche, Magenta Therapeutics, MedDay, Merck Serono, Novartis, Sanofi-Genzyme, and Teva. M Filippi has received consulting and\/or speaking fees from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva, and research support from Biogen, Merck-Serono, Novartis, Roche, and Teva. HL Weiner has received consulting fees from Biodextris, Biogen, CBridge Capital, Everest Medicines, Genentech, Tiziana, Tilos, IM Therapeutics, Magnolia, MedDay, and vTv, and research support from Biogen, EMD Serono, Genentech, Sanofi-Genzyme, Google, Novartis; Teva, Tilos, and Verily. R Bakshi has received consulting fees from Bayer, Biogen, BMS\/Celgene, EMD Serono, Genentech, and Novartis, and research support from BMS\/Celgene, EMD Serono, and Sanofi-Genzyme. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All patients provided consent to be anonymously included in this report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have consented to publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}